Recently, the BCL-2 inhibitor venetoclax exhibited excellent efficacy when combined with endocrine therapy for estrogen receptor-positive breast cancers [7] and entered testing for the treatment of HER2-positive breast cancers overall and TNBCs in particular. The gene discussed is BCL2; the disease is breast carcinoma.